Table 3 Percentage of patients on monotherapy according to the biologic treatment
1st Course | 2nd Course | 3rd Course | 4th Course | Total | |
|---|---|---|---|---|---|
N Patients on adalimumab monotherapy/patients on adalimumab (%) | 5/27 (18) | 2/3(67) | - | - | 7/30 (23) |
N patients on etanercept monotherapy/patients on etanercept (%) | 12/39 (31) | 4/6 (67) | 1/1 (100) | - | 17/46 (37) |
N patients on Infliximab monotherapy/patients on Infliximab (%) | 0/7(0) | 1/1 (100) | 0/0 | 0/0 | 1/8 (12) |
N patients on Abatacept monotherapy/patients on Abatacept (%) | 1/1 (100) | 6/10 (60) | 0/3 (0) | 1/1 (100) | 8/15 (53) |
N patients on Rituximab monotherapy/patients on Rituximab (%) | 1/5 (20) | 0/2 (0) | 0/1 (0) | 1/1 (100) | 2/9 (22) |
N patients on Tocilizumab monotherapy/patients on Tocilizumab (%) | 0/0 (0) | 2/2 (100) | 3/4 (75) | 0/0 (0) | 5/6 (83) |